Nuvation Bio Inc (NUVB) — Institutional Investor Activity (Q2 2026)

NUVB ranks #2550 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

NUVB is a top-conviction position for Omega Fund Management, LLC — at 24.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in NUVB belongs to FMR LLC, but the position matters far more to Omega Fund Management, LLC, who has 24.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

UBS Group AG has added to its NUVB position for two straight quarters, increasing it by $37.0M to reach $42.6M today.

Qube Research & Technologies Ltd has trimmed its NUVB position for two straight quarters, cutting it by $9.8M while still holding $1.6M.

NUVB is down 4.7% today, but institutions show net buying of $185.3M this quarter — a divergence between today's price move and the underlying institutional flow.

NUVB reported a net loss of $149.8M over the trailing twelve months.

• Not yet profitable — net loss of $149.8M over the trailing twelve months
• Revenue grew 1083.6% year over year
• Net income improved year over year, from -$202.9M to -$149.8M
• Operating cash flow was negative, using $173.4M in cash
• Current ratio of 6.95x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.95x equity — within a conventional range